Impact of Tenofovir Disoproxil Fumarate Use During Pregnancy on Maternal Bone Mineral Density

Pediatr Infect Dis J. 2022 Dec 1;41(12):976-978. doi: 10.1097/INF.0000000000003719. Epub 2022 Oct 11.

Authors

Liming Wang¹, Athena P Kourtis², Jeffrey Wiener², Lili Chen³, Wei Liu⁴, Bo Fan⁵, John Shepherd⁵, Marc Bulterys¹

Affiliations

¹ From the Global AIDS Program - China Office, U.S. Centers for Disease Control and Prevention (CDC), Beijing, China.
² Division of HIV Prevention, CDC, Atlanta, GA.
³ Guangxi Provincial Center for Disease Control and Prevention, Nanning, China.
⁴ Guangxi Zhuang Autonomous Region Health and Family Planning Commission, Nanning, China.
⁵ Department of Epidemiology & Biostatistics, University of California San Francisco, CA.

PMID: 36219873
DOI: 10.1097/INF.0000000000003719

No abstract available

MeSH terms

Anti-HIV Agents* / therapeutic use
Bone Density
Female
HIV Infections* / drug therapy
Humans
Pregnancy
Tenofovir / adverse effects
Viral Load

Substances

Tenofovir
Anti-HIV Agents